Category: NICE

JGrimes
The UK body that decides which drugs are cost-effective is often attacked when it decides new treatments that offer only small benefits aren’t worth a high price. But in an interview published in the Observer this weekend, Sir Michael Rawlins, the chairman of the National Institute for Health and Clinical Excellence (NICE), comes […]

JGrimes
An expensive new breast cancer drug isn’t effective enough to justify its cost, expert advisers in the U.K. said today.
The drug, GlaxoSmithKline’s Tyverb (sold in the U.S. as Tykerb), would cost about £20,000 per year (or nearly $40,000); total costs associated with administering the drug are about £80,000 (or nearly $160,000), Dow Jones […]